[1]何涛君,吴正林,钟小强,等.乙肝患者HBV载量与IgA,IgG,IgM及C3,C4相关性研究[J].现代检验医学杂志,2015,30(04):67-70.[doi:10.3969/j.issn.1671-7414.2015.04.018]
 HE Tao-jun,WU Zheng-lin,ZHONG Xiao-qiang,et al.Study on the Relationship between Patients with Hepatitis B Viral Loads and Immunoglobulin A,G,M and Complement C3,C4[J].Journal of Modern Laboratory Medicine,2015,30(04):67-70.[doi:10.3969/j.issn.1671-7414.2015.04.018]
点击复制

乙肝患者HBV载量与IgA,IgG,IgM及C3,C4相关性研究()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年04期
页码:
67-70
栏目:
论著
出版日期:
2015-08-10

文章信息/Info

Title:
Study on the Relationship between Patients with Hepatitis B Viral Loads and Immunoglobulin A,G,M and Complement C3,C4
文章编号:
1671-7414(2015)04-067-04
作者:
何涛君吴正林钟小强聂署萍陆学东
广东医学院附属福田医院检验医学部,广东深圳 518033
Author(s):
HE Tao-junWU Zheng-linZHONG Xiao-qiangNIE Shu-pingLU Xue-dong
Department of Clinical Laboratory,the Affiliated Futian Hospital of Medical College of Guangdong,Guangdong Shenzhen 518033,China
关键词:
乙型肝炎 HBV载量 IgA IgG IgM 补体C3C4
分类号:
R512.62; R392.11
DOI:
10.3969/j.issn.1671-7414.2015.04.018
文献标志码:
A
摘要:
目的 旨在探讨深圳市乙肝患者HBV-DNA与免疫球蛋白(IgA,IgG,IgM)和补体(C3,C4)的关系。方法 首先采用实时荧光定量PCR技术检测210例乙肝患者的HBV-DNA,按检测结果10ncopies/ml进行分组,可分为102~108 copies/ml 7组实验组。然后对7组实验组和对照组同时进行IgA,IgG,IgM及C3,C4检测,分析乙肝患者HBV-DNA与IgA,IgG,IgM及C3,C4的相关性。结果 乙肝患者HBV-DNA为105~108 copies/ml时,均出现了IgA,IgG,IgM的增高(U=12.43,10.96,6.42,P<0.01)及C3,C4的降低(U=8.37,6.0,P<0.01),而在102~104 copies/ml只出现IgA和IgM的增高(U=2.36,2.04,P<0.05),其他指标差异均无统计学意义。在7组实验组的两两比较中,只有104组与105组出现了显著性的变化(IgA,IgM增高,C4降低; U=2.39,2.46,2.09,P<0.05,IgG增高,U=3.25,P<0.01),而其他低载毒量组之间和高载毒量组之间均无显著性差异。结论 乙肝患者体内不同的HBV载量会引起IgA,IgG,IgM及C3,C4相应的改变,特别是当HBV载量为105~108copies/ml的4个实验组,伴随着HBV-DNA的增高均出现IgA,IgG,IgM增高及C3,C4降低,严重的影响了机体免疫功能,两者呈正相关(r=0.967,P<0.01)。104组与105组各指标出现显著性改变,提示对乙肝患者的抗病毒护肝治疗中,要尽量将HBV载量控制在104 copies/ml以下,才能达到最小程度损伤免疫功能的疗效。
Abstract:
Objective To investigate the relationship between Hepatitis B patients with different viral loads and immunoglobulin A,G,M and complement C3,C4.Methods Firstly,followed by real-time fluorescence quantitative PCR detection 210 cases ofhepatitis B patients with HBV-DNA levels,according to 10n copies/ml different viral load detection results,it was divided into 102~108 copies/ml ofthe experimental groups.Then the experimental groups and control group were simultaneously detected in immunoglobulin A,G,M and complement C3,C4.Analysed the correlation between HBV loads and immunoglobulin A,G,M and complement C3,C4.Results When the viral loads of hepatitis B patients were 105~108 copies/ml,the testing results of IgA,IgG and IgM were both increasing(U=12.43,10.96,6.42,P<0.01),while C3 and C4 were both decreasing(U=8.37,6.0,P<0.01).When the viral loads of hepatitis B patients were 102~104 copies/ml,only IgA and IgM were increasing(U=2.36,2.04,P<0.05),the other testing results had no statistical significance.Between the test of 7 experimental groups compared with each other,only 104 groupand 105 group had significantly changed(IgA and IgM were increasing,C4 wasdecreasing,U=2.39,2.46,2.09,P<0.05,IgG was increasing,U=3.25,P<0.01),but between other low viral loads or high viral loads were not significantly differences.Conclusion The different viralloads of hepatitis B patients could cause the different changes of immunoglobulin A,G,M and complement C3,C4,especially in the 4 groups from 105 to 108 copies/ml.Followed by increasing in viral loads,there were immunoglobulinA,G,M increasing and complement C3,C4 decreasing,and also serious impactionon the immune function of organism.There was a positive correlation between viral loads in vivo and immune damages,correlation coefficient(γ =0.967,P<0.01).When the viral loads from 104 to 105 copies/ml,the testing resultshad changed significantly.It suggest that should control viral loads under 104 copies/ml in the hepatitis B antiviral treatment,so the effect of immunefunction damage will be the minimum.

参考文献/References:

[1] 张青梅,任传梅.HBV感染相关疾病患者AFP和HBVDNA定量结果分析[J].现代检验医学杂志,2014,29(1):128-130.
Zhang QM,Ren CM.Analysis of related diseases in patients with AFPand HBVDNA quantitative results of HBV infection[J].Journal of Modern Laboratory Medicine,2014,29(1):128-130.
[2] 谭玉华,林艳芬,廖思红,等.时间分辨荧光免疫法检测HBV PreS1Ag试剂盒的应用评价[J].现代检验医学杂志,2013,23(6):58-62.
Tan YH,Lin YF,Liao SH,et al.Application value of time-resolvedfluoroimmunoassay for detecting hepatitis B virus PreS1Ag[J].Journal of Modern Laboratory Medicine,2013,23(6):58-62.
[3] 汪 浩,邹文静.时间分辨荧光免疫分析法测定乙型肝炎HBsAg的临床价值分析[J].吉林医学,2015,36(2):310.
Wang H,Zou WJ.Time resolved analysis of the clinical value of determination of hepatitis B HBsAg fluorescence immunoassay[J].Jilin Medical Journal,2015,36(2):310.
[4] 王 方,石婷婷,刘丽儿.慢性乙型肝炎患者免疫球蛋白检验的临床探讨[J].中医临床研究,2014,6(24):69-70.
Wang F,Shi TT,Liu LE.Clinical study on immune globulin test of patients with chronic hepatitis B[J].Clinical Journal of Chinese Medicine,2014,6(24):69-70.
[5] 张建刚.肝炎病毒抗原抗体标志物与HBV-DNA联合检测的相关性探讨[J].中国继续医学教育,2014,6(8):124-126.
Zhang JG.The relationship between the joint detection mark and HBV-DNA antibody to hepatitis virus antigen[J].China Continuing Medical Education,2014,6(8):124-126.
[6] 单芙香,卢紫燕,刘 刚,等.2004~2013年深圳市乙型病毒性肝炎流行特征分析[J].微生物学免疫学进展,2014,42(6):49-52.
Shan FX,Lu ZY,Liu G,et al.Analysis on the epidemiological characteristics of hepatitis B in Shenzhen in 2004~2013[J].Prog in Microbiol Immunol,2014,42(6):49-52.
[7] 杨国绘,许文龙,窦琳琳,等.1 128例HBV-DNA定量和乙肝血清学标志物定量结果之间的相关性研究[J].中国卫生检验杂志,2013,23(2):351-354.
Yang GH,Xu WL,Dou LL,et al.Study on relationship between the quantitive detection of HBV DNA and serological markers in 1 128 hepatitis B patients[J].Chinese Journal of Health Laboratory Technology,2013,23(2):351-354.
[8] 张 文,张红玉,曾年伟.HBeAg定量阳性和乙肝DNA的相关性研究及临床价值[J].现代医药卫生,2011,27(3):338-339.
Zhang W,Zhang HY,Zeng NW.Correlation resarch and HBeAg quantitative positive with HBV DNA and its clinical value[J].Modern Medicine & Health,2011,27(3):338-339.
[9] 乔 莹,黄 芬,蔡鑫泽,等.HBV感染诱发AID高表达与肝细胞癌变相关性研究[J].中华肿瘤防治杂志,2015,22(1):13-18.
Qiao Y,Huang F,Cai XZ,et al.Relation between hepatocellular carcinogenesis and an aberrant expression of activation induced deaminase triggeredby chronic HBV infection[J].Chinese Journal of Cancer Prevention and Treatment,2015,22(1):13-18.
[10] 王 颖,刘胜军,杨飞兰,等.乙型肝炎病毒检测YMDD基序变异情况分析[J].现代检验医学杂志,2013,28(6):69-71,75.
Wang Y,Liu SJ,Yang FL,et al.Analysis of hepatitis B virus' YMDD motifmutations[J].Journal of Modern Laboratory Medicine,2013,28(6):69-71,75.
[11] 张 静.重组人干扰素α-2b注射液治疗儿童慢性乙型肝炎疗效分析[J].中国实用医药,2015,10(2):118-119.
Zhang J.Analysis of therapeutic effect of interferon alpha -2b injectionin the treatment of children with chronic hepatitis B recombinant human[J].China Practical Medicine,2015,10(2):118-119.

相似文献/References:

[1]褚小慧.慢性乙型肝炎患者血清HBV DNA,HBeAg和ALT滴度与恩替卡韦疗效的关系[J].现代检验医学杂志,2015,30(02):142.[doi:10.3969/j.issn.1671-7414.2015.02.045]
 ZHU Xiao-hui.Relationship between the Level of HBV DNA,ALT and the Titers of HBeAg with Effects of Entecavir in Chronic Hepatitis B Patients[J].Journal of Modern Laboratory Medicine,2015,30(04):142.[doi:10.3969/j.issn.1671-7414.2015.02.045]
[2]黄 允,李 艳,彭 锐,等.HBV感染致肝损伤患者CRP,hsCRP和SAA临床价值的探讨[J].现代检验医学杂志,2017,32(02):49.[doi:10.3969/j.issn.1671-7414.2017.02.013]
 HUANG Yun,LI Yan,PENG Rui,et al.Clinical Significance of SAA,CRP and hsCRP in HBV Hepatopathy Patients[J].Journal of Modern Laboratory Medicine,2017,32(04):49.[doi:10.3969/j.issn.1671-7414.2017.02.013]

备注/Memo

备注/Memo:
基金项目:2014年深圳市福田区卫生公益性科研项目(FTWS2014006)。
作者简介:何涛君(1981-),女,硕士,副主任检验师,主要从事生化及免疫检验工作,Tel:15986686103,E-mail:hetaojun2005@126.com。
更新日期/Last Update: 2015-08-10